<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705584</url>
  </required_header>
  <id_info>
    <org_study_id>17101246</org_study_id>
    <nct_id>NCT04705584</nct_id>
  </id_info>
  <brief_title>Topical Immuonosuppressant Drugs in Spring Catarrh</brief_title>
  <official_title>Role of Topical Immuonosuppressant in the Management of Spring Catarrh: a Comparative Study Between Cyclosporine A 2% and Tacrolimus 0.3%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spring catarrh is a prevalent type of conjunctival allergic disorder in temperate countries.&#xD;
      Topical steroids are the cornerstone management of spring catarrh beside other anti allergic&#xD;
      drugs. However, prolonged use of topical steroids especqially in resistant spring catarrh&#xD;
      carries risk of ocular side effects as 2nd glaucoma and cataract. We will investigate the&#xD;
      safety and efficacy of topical immuonosuppressant in the management of resistant spring&#xD;
      catarrh as an alternative to steroid therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vernal keratoconjunctivitis (VKC) (spring catarrh) is an allergic disease that affects&#xD;
      children and young adults and is one of the most severe forms of atopic ocular disease.&#xD;
      Classically, the incidence of VKC peaks in the summer and spring. However, 60% of cases can&#xD;
      become chronic with persistent symptoms. VKC is mainly characterized by intense itching, but&#xD;
      patients also frequently complain of lacrimation, foreign body sensation and photophobia.&#xD;
&#xD;
      There are three different clinical forms of VKC; the palpebral form, which is characterized&#xD;
      by giant papillae in the upper tarsal; the limbal form, with gelatinous nodules composed of&#xD;
      eosinophilic infiltrates and degenerated epithelial cells (Horner- Tantra spots) and a mixed&#xD;
      form.&#xD;
&#xD;
      The treatment of VKC involves the use of topical Anti-histaminic and Mast Cell Stabilizers,&#xD;
      which are usually sufficient to control symptoms in mild cases. However, a high number of&#xD;
      patients are refractory to allergy therapy and require treatment with topical steroids. Side&#xD;
      effects related to long-term steroid use, such as increased intraocular pressure (IOP),&#xD;
      cataract development and increased susceptibility to infections.&#xD;
&#xD;
      Refractory VKC, development of steroid complications or the need for long-term use of Topical&#xD;
      steroids are indications to use Topical immune-suppressant drugs as Tacrolimus (TCL) or&#xD;
      Cyclosporine A (CsA). Tacrolimus is an immunosuppressant derived from Streptomyces&#xD;
      tsukubaensis, is an alternative to steroid therapy for allergic diseases of the ocular&#xD;
      surface. Topical Cyclosporine A is a fungal metabolite that reduces ocular inflammation by&#xD;
      inhibiting Th2 lymphocyte proliferation and histamine release from mast cells and basophils.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular surface changes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in papillary conjunctival reaction, conjunctival redness, Tranta spots and gelatinous masses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular symptoms changes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of ocular symptoms as documented by the patient as redness, itching and discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure changes</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean change of intraocular pressure from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface toxicity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Development of corneal or conjunctival toxic effects as corneal epithelial defects or chronic conjunctival follicular reaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Vernal Keratoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Topical steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by 4 times daily for 2 weeks, then twice daily for 2 weeks and finally once daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Cyclosporine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Cyclosporine A 2% Topical eye drops 2 times per day for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Tacrolimus A 0.3% Topical eye drops 2 times per day for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone (as Acetate)</intervention_name>
    <description>Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.</description>
    <arm_group_label>Topical steroids</arm_group_label>
    <other_name>Predforte Eye drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CycloSPORINE Ophthalmic Suspension</intervention_name>
    <description>This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.</description>
    <arm_group_label>Topical Cyclosporine A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTacrolimus Topical</intervention_name>
    <description>This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.</description>
    <arm_group_label>Topical Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from Vernal Keratoconjunctivitis refractory to conventional&#xD;
             treatments (Topical Anti-histaminic agents, Mast-cell stabilizer and steroids) are&#xD;
             included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contact lens wearer. Patient with one functioning eye. Patients with any other active&#xD;
             ocular inflammatory conditions. Patients with hypersentivity reaction to either&#xD;
             Cyclosporine A or Tacrolimus. Loss of 2 or more follow up visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zeiad H Eldaly, MD</last_name>
    <phone>002-0109-4544-721</phone>
    <email>dr_ziadeldaly@aun.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut University Hospital</name>
      <address>
        <city>Assiut</city>
        <zip>71516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Zeiad H Eldaly</last_name>
      <phone>002-0109-4544-722</phone>
      <email>dr_ziadeldaly@aun.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 10, 2021</last_update_submitted>
  <last_update_submitted_qc>January 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Zeiad Eldalyl</investigator_full_name>
    <investigator_title>Lecturer of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Resistant spring catarrh</keyword>
  <keyword>Cyclosporine A</keyword>
  <keyword>Tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

